|Day Low/High||72.64 / 73.37|
|52 Wk Low/High||64.27 / 89.54|
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Drug Administration (CNDA) has approved Genvoya ® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1...
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2018.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F.
Is the pharma sector fever heating up in 2H18? Drug investors, get ready as there could be some good trades to be made.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results of a retrospective nationwide analysis of the impact of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) for pre-exposure prophylaxis (PrEP) use across all 50 U.
Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V.
Some beaten up biotech names are finally coming back to life. Here's a look at the technical analysis.
Investors have never gone wrong buying Netflix on the dips. Jim Cramer tells you what to make of the 'FANG Musketeers.'
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes.
Kite, a Gilead Company (NASDAQ: GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
This biotech's weekly chart is very encouraging.
Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company's Marketing Authorization Application (MAA) for Yescarta ®...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the European Commission has granted Marketing Authorization for Biktarvy ® (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF), a once-daily single tablet regimen (STR)...
Jim Cramer takes a look at Snap, Gilead Sciences, Cronos Group, TrustCo Bank, CRISPR Therapeutics, Iron Mountian, Prudential and more.
Trump's doubling down on trade issues. If you can't stand the pressure, then raise cash. Jim Cramer has your game plan for next week.
Looking for stocks that could outperform during the current period of labor inflation? Try building a portfolio of these 50 stocks.
Here is a new index for all you traders out there to follow, compliments of TheStreet's founder Jim Cramer. Welcome to the GLUM Index.
Taking the measure of what's keeping the markets in the dumps.
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that John McHutchison, MD, Chief Scientific Officer and Head of Research and Development, has been appointed an Officer of the Order of Australia in recognition of his "distinguished service to medical...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of Andrew Dickinson to Executive Vice President, Corporate Development and Strategy, with responsibility for Gilead's corporate development, alliance management, competitive intelligence,...
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
Kite, a Gilead Company (Nasdaq: GILD), today announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.